BackNewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV Total Liabilities

Track NewAmsterdam Pharma Company NV's total liabilities ($67M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$67.42M
↑ 64.24% YoYΔ $26.37M vs prior year quarter

Peer average

Loading

NewAmsterdam Pharma Company NV Total Liabilities History

Loading

NewAmsterdam Pharma Company NV vs. peers: Total Liabilities Comparison

Loading

NewAmsterdam Pharma Company NV Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NewAmsterdam Pharma Company NV (NAMS) FAQ

NewAmsterdam Pharma Company NV posts a total liabilities of $67M as of March 2026. That compares with $41M in the prior-year period — up 64.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, NewAmsterdam Pharma Company NV's total liabilities was $41M. The latest reading is $67M — a 64.2% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of NewAmsterdam Pharma Company NV's financial statement story. At $67M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NAMS's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; NewAmsterdam Pharma Company NV's other metric pages and overview cover the third.